Skip to main content

Table 1 Eligibility criteria

From: Benefits and harms of screening for and treatment of asymptomatic bacteriuria in pregnancy: a systematic review

  Questions 1 and 2 (ASB screening) Question 3 (ASB treatment)
Population • Pregnant women taking part in routine maternal care
• Without symptoms of UTI
• With unknown ASB status
• Pregnant women with ASB detected in screening
Study intervention • Any ASB screening strategy followed by treatment, if necessary • Any treatment for ASB
Control intervention • No ASB screening, but treatment if symptoms of UTI occur (question 1)
• Any other ASB screening strategy followed by treatment, if necessary (question 2)
• No treatment or placebo
Patient-relevant outcomes • Pyelonephritis
• UTI
• Symptoms linked directly or indirectly to UTI (e. g. headache or visual impairment as symptoms of pre-eclampsia, fever)
• Infant morbidity (e. g. respiratory distress syndrome, sepsis, cerebral haemorrhage, necrotising enterocolitis)
• Perinatal mortality
• Early preterm birth (< 32 weeks of gestation)
• Very low birth weight (< 1500 g)
• Health-related quality of life and psychosocial functioning
• Any adverse event
  1. ASB asymptomatic bacteriuria, UTI urinary tract infection